TY - JOUR
T1 - Precision Medicine and/or Biomarker Based Therapy in T2DM
T2 - Ready for Prime Time?
AU - Rossing, Peter
AU - Frimodt-Møller, Marie
AU - Persson, Frederik
N1 - Copyright © 2023 Elsevier Inc. All rights reserved.
PY - 2023/10/18
Y1 - 2023/10/18
N2 - Approximately 30-40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.
AB - Approximately 30-40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.
UR - http://www.scopus.com/inward/record.url?scp=85174726199&partnerID=8YFLogxK
U2 - 10.1016/j.semnephrol.2023.151430
DO - 10.1016/j.semnephrol.2023.151430
M3 - Review
C2 - 37862744
SN - 0270-9295
VL - 43
SP - 151430
JO - Seminars in Nephrology
JF - Seminars in Nephrology
IS - 3
M1 - 151430
ER -